Literature DB >> 9743149

Specialists achieve better outcomes than generalists for lung cancer surgery.

G A Silvestri1, J Handy, D Lackland, E Corley, C E Reed.   

Abstract

OBJECTIVE: A push toward care provided by generalists as opposed to specialists has occurred in the health-care marketplace despite a lack of provider specific outcome data. The objective of this study was to determine whether the outcome of patients undergoing lung cancer surgery is different between general surgeons (GSs) and thoracic surgeons (TSs).
DESIGN: Examination of data from a state-wide severity-adjusted administrative hospital discharge database. SETTING/PARTICIPANTS: Patients undergoing lung cancer resection in all nonfederal acute care hospitals within South Carolina. MAIN OUTCOME MEASURES: Mortality by specialty adjusted for case mix.
RESULTS: From 1991 to 1995, 1,720 resections for lung cancer were performed in South Carolina. One hundred thirty-seven cases were excluded because surgeons did not meet the predefined criteria for board certification, leaving 1,583 resections for analysis. One-half of lobectomies and nearly 60% of pneumonectomies were performed by GSs. Patients were similar in age, sex, gender, race, and the proportion in each severity of illness subclass. Mortality was significantly higher in patients who underwent lobectomy by GSs vs TSs (5.3% vs 3.0%; p<0.05) and in patients with extreme comorbidities (43.6% vs 25.4%; p=0.03) or age >65 years (7.4% vs 3.5%; p<0.05). Seventy percent of TSs performed > 10 cases in the series, whereas 75% of GSs performed <10 (p=0.05). Logistic regression analysis failed to identify any significant variable that might explain the mortality differences between TSs and GSs.
CONCLUSION: Mortality is lower for lung cancer resection when the surgery is performed by a TS.

Entities:  

Mesh:

Year:  1998        PMID: 9743149     DOI: 10.1378/chest.114.3.675

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality.

Authors:  A S Rosemurgy; M Bloomston; F M Serafini; B Coon; M M Murr; L C Carey
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

2.  Improving lung cancer outcomes by improving the quality of surgical care.

Authors:  Raymond U Osarogiagbon; Thomas A D'Amico
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 3.  What is quality, and can we define it in lung cancer?-the case for quality improvement.

Authors:  Farhood Farjah; Frank C Detterbeck
Journal:  Transl Lung Cancer Res       Date:  2015-08

4.  Initial clinical outcomes after completion of training in a Canadian Royal College thoracic surgery program.

Authors:  Steven Milman; Thomas Ng
Journal:  Can J Surg       Date:  2006-12       Impact factor: 2.089

5.  Risk and benefit: the eternal Yin and Yang of thoracic surgery.

Authors:  Alex G Little
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

6.  Hospital volume and surgical outcomes of lung cancer in Japan.

Authors:  Hiroaki Osada; Etsuko Yamakoshi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-09

7.  [Minimum quantities from a thoracic surgical standpoint].

Authors:  D Kaiser
Journal:  Chirurg       Date:  2007-11       Impact factor: 0.955

8.  [Development of thoracic surgery over the next 20 years].

Authors:  H Hoffmann; H Dienemann
Journal:  Chirurg       Date:  2009-12       Impact factor: 0.955

9.  Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease.

Authors:  Nichole T Tanner; Lin Dai; Brett C Bade; Mulugeta Gebregziabher; Gerard A Silvestri
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

10.  Impact of hospital teaching status on survival from ruptured abdominal aortic aneurysm repair.

Authors:  Robert A Meguid; Benjamin S Brooke; Bruce A Perler; Julie A Freischlag
Journal:  J Vasc Surg       Date:  2009-05-15       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.